Medical Use
Sarclisa is a CD38-directed cytolytic antibody used in combination with pomalidomide and dexamethasone to treat adult patients with multiple myeloma. It is indicated for those who have previously received at least two therapies, including lenalidomide and a proteasome inhibitor.
Recommended Dosage:
- -The recommended dose is 10 mg/kg, administered as an intravenous infusion.
- -For the first 4 weeks, infusions are given weekly.
- -After the initial 4 weeks, infusions are administered every 2 weeks.
- -Treatment continues with pomalidomide and dexamethasone until disease progression or unacceptable toxicity occurs.
- -Each treatment cycle typically spans 28 days.
- -If a scheduled dose is missed, administer it as soon as possible and adjust the treatment schedule to maintain the appropriate interval.
Warning & Precautions
The use of isatuximab-irfc injections (100 mg / 500 mg) is contraindicated in patients with severe hypersensitivity to isatuximab-irfc or any of its excipients.
Infusion-related reactions have been observed in patients treated with isatuximab-irfc. To mitigate these reactions, premedicate patients with acetaminophen, diphenhydramine, H2 antagonists, or equivalent, and dexamethasone before the infusion.
Neutropenia may occur with Sarclisa (isatuximab-irfc) 100 mg injections. Regularly monitor complete blood counts (CBC) during treatment. Consider prophylactic antibiotics and antivirals, and assess patients with neutropenia for signs and symptoms of infection.
Monitor vital signs and symptoms closely throughout the isatuximab infusion. For patients experiencing Grade 1 or 2 reactions, interrupt the infusion and provide appropriate medical care.
Due to its mechanism of action, Sarclisa (500 mg or 100 mg) can cause fetal harm if administered to a pregnant woman, potentially leading to fetal immune cell depletion and reduced bone density.
In some cases, second primary malignancies have been reported. Patients should be monitored for the development of second primary malignancies according to IMWG guidelines.
Documentation Availability
Documents required to import SARCLISA to India?
SARCLISA (isatuximab-irfc) injection can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing SARCLISA (Cancer Treatment Medicines) from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
What is the generic name for the trade name drug Sarclisa®?
The generic name for Sarclisa® is isatuximab-irfc.
Who manufactures Sarclisa®?
Sarclisa® is manufactured by Sanofi.
Is Sarclisa® approved by the FDA?
Yes, Sarclisa® received FDA approval on March 31, 2021.
What is Sarclisa®?
Sarclisa® (isatuximab injection) is the latest anti-CD38 monoclonal antibody approved for treating multiple myeloma (MM).
What is the dosage form of Sarclisa®?
Sarclisa® is available as injections in two strengths: 100 mg/5 mL (20 mg/mL) and 500 mg/25 mL (20 mg/mL) for intravenous use.
What are the common side effects of Sarclisa®?
Common side effects include upper respiratory tract infections, neutropenia, infusion-related reactions, pneumonia, and diarrhea.
How much does Sarclisa® cost in India?
Sarclisa® is reasonably priced in India. For authentic procurement, you can contact the Rx4u team.
What are the storage conditions for Sarclisa®?
Store Sarclisa® vials in a refrigerator at 36°F to 46°F (2°C to 8°C) in their original carton to protect from light. Do not freeze or shake.
Is it safe to buy Sarclisa® online in India?
Yes, you can safely purchase Sarclisa® online in India through https://rx4u.in/.
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
